Akari Therapeutics ADR (AKTX)

Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload...

Akari Therapeutics (NASDAQ: AKTX) continues to execute on its strategy of advancing a differentiated payload platform designed for the next generation of antibody drug conjugates (ADCs). The

Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform Watch the “What...

TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing...

Akari Therapeutics is advancing a novel antibody-drug conjugate (ADC) payload designed to overcome the limitations of existing cancer therapies, with its lead candidate AKTX-101 approaching c

Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing...

TAMPA, Fla. and LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing...

Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future potential Access the Akari CEO Corner here TAMPA, Fla. and LONDON,...

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers  Watch the “What This Means” video here TAMPA, Fla. and...

An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer models Data supports...